| Combination therapy to checkmate Glioblastoma: clinical challenges and advances D Ghosh, S Nandi, S Bhattacharjee Clinical and translational medicine 7 (1), 33, 2018 | 189 | 2018 |
| The FANCM ortholog Fml1 promotes recombination at stalled replication forks and limits crossing over during DNA double-strand break repair W Sun, S Nandi, F Osman, JS Ahn, J Jakovleska, A Lorenz, MC Whitby Molecular cell 32 (1), 118-128, 2008 | 173 | 2008 |
| Short-term expansion of breast circulating cancer cells predicts response to anti-cancer therapy BL Khoo, SC Lee, P Kumar, TZ Tan, ME Warkiani, SGW Ow, S Nandi, ... Oncotarget 6 (17), 15578, 2015 | 171 | 2015 |
| Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo MA Tyler, IV Ulasov, AM Sonabend, S Nandi, Y Han, S Marler, J Roth, ... Gene therapy 16 (2), 262-278, 2009 | 155 | 2009 |
| Structural basis of Mcm2-7 replicative helicase loading by ORC-Cdc6 and Cdt1 LH Yuan Z, Riera A, Bai L, Sun J, Nandi S, Spanos C, Chen ZA, Barbon M ... Nat Struct Mol Biol 24 (3), 316-324, 2017 | 142 | 2017 |
| The FANCM family of DNA helicases/translocases MC Whitby DNA repair 9 (3), 224-236, 2010 | 130 | 2010 |
| The fission yeast FANCM ortholog directs non-crossover recombination during meiosis A Lorenz, F Osman, W Sun, S Nandi, R Steinacher, MC Whitby Science 336 (6088), 1585-1588, 2012 | 116 | 2012 |
| FANCG promotes formation of a newly identified protein complex containing BRCA2, FANCD2 and XRCC3 JB Wilson, K Yamamoto, AS Marriott, S Hussain, P Sung, ME Hoatlin, ... Oncogene 27 (26), 3641-3652, 2008 | 111 | 2008 |
| DNA damage response and cancer therapeutics through the lens of the Fanconi Anemia DNA repair pathway S Bhattacharjee, S Nandi Cell Communication and Signaling 15 (1), 41, 2017 | 84 | 2017 |
| Choices have consequences: the nexus between DNA repair pathways and genomic instability in cancer S Bhattacharjee, S Nandi Clinical and translational medicine 5, 1-8, 2016 | 82 | 2016 |
| Synthetic lethality in DNA repair network: A novel avenue in targeted cancer therapy and combination therapeutics S Bhattacharjee, S Nandi IUBMB Life 69 (12), 929-937, 2017 | 72 | 2017 |
| CRISPR–Cas9 a boon or bane: the bumpy road ahead to cancer therapeutics D Ghosh, P Venkataramani, S Nandi, S Bhattacharjee Cancer cell international 19, 1-10, 2019 | 68 | 2019 |
| RNA interference: potential therapeutic targets S Jana, C Chakraborty, S Nandi, JK Deb Applied microbiology and biotechnology 65, 649-657, 2004 | 68 | 2004 |
| Transcription factors that govern development and disease: an achilles heel in cancer D Huilgol, P Venkataramani, S Nandi, S Bhattacharjee Genes 10 (10), 794, 2019 | 54 | 2019 |
| Rare genetic diseases with defects in DNA repair: opportunities and challenges in orphan drug development for targeted cancer therapy S Bhattacharjee, S Nandi Cancers 10 (9), 298, 2018 | 43 | 2018 |
| Fibrin biomaterials for tissue regeneration and repair E Sproul, S Nandi, A Brown Peptides and proteins as biomaterials for tissue regeneration and repair …, 2018 | 41 | 2018 |
| Fanconi Anemia D Liu Handbook of Tumor Syndromes, 589-595, 2020 | 28 | 2020 |
| A high-throughput mechanofluidic screening platform for investigating tumor cell adhesion during metastasis A Spencer, C Spruell, S Nandi, M Wong, M Creixell, AB Baker Lab on a Chip 16 (1), 142-152, 2016 | 28 | 2016 |
| The ATPase activity of Fml1 is essential for its roles in homologous recombination and DNA repair S Nandi, MC Whitby Nucleic acids research 40 (19), 9584-9595, 2012 | 25 | 2012 |
| Phosphorylation of MCT-1 by p44/42 MAPK is required for its stabilization in response to DNA damage S Nandi, LS Reinert, A Hachem, K Mazan-Mamczarz, P Hagner, H He, ... Oncogene 26 (16), 2283-2289, 2007 | 25 | 2007 |
